SG10201405259PA - Novel antagonist antibodies and their fab fragments against gpvi and uses thereof - Google Patents

Novel antagonist antibodies and their fab fragments against gpvi and uses thereof

Info

Publication number: SG10201405259PA
Authority: SG; Singapore
Prior art keywords: fab fragments; antagonist antibodies; fragments against; novel antagonist; against gpvi
Prior art date: 2009-12-18

Application number

SG10201405259PA

Other languages

English (en)

Inventor

Nicolas Baurin

Francis Blanche

Béatrice Cameron

Carsten Corvey

Tarik Dabdoubi

Christian Engel

Peter Florian

Ingo Focken

Katja Kroll

Jochen Kruip

Christian Lange

Thomas Langer

Martin Lorenz

Vincent Mikol

Ercole Rao

Peter Wonerow

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-12-18

Filing date

2010-12-17

Publication date

2014-10-30

2009-12-18 Priority claimed from EP09306283A external-priority patent/EP2336188A1/en

2010-06-21 Priority claimed from EP10305660A external-priority patent/EP2397495A1/en

2010-07-01 Priority claimed from EP10305721A external-priority patent/EP2402371A1/en

2010-12-17 Application filed by Sanofi Sa filed Critical Sanofi Sa

2014-10-30 Publication of SG10201405259PA publication Critical patent/SG10201405259PA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Heart & Thoracic Surgery (AREA)
Toxicology (AREA)
Hematology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Analytical Chemistry (AREA)
Urology & Nephrology (AREA)
Radiology & Medical Imaging (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Mycology (AREA)
Vascular Medicine (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

SG10201405259PA 2009-12-18 2010-12-17 Novel antagonist antibodies and their fab fragments against gpvi and uses thereof SG10201405259PA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP09306283A EP2336188A1 (en)	2009-12-18	2009-12-18	Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof
EP10305660A EP2397495A1 (en)	2010-06-21	2010-06-21	Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof
EP10305721A EP2402371A1 (en)	2010-07-01	2010-07-01	Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof

Publications (1)

Publication Number	Publication Date
SG10201405259PA true SG10201405259PA (en)	2014-10-30

Family

ID=44060924

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG10201405259PA SG10201405259PA (en)	2009-12-18	2010-12-17	Novel antagonist antibodies and their fab fragments against gpvi and uses thereof
SG2012043956A SG181707A1 (en)	2009-12-18	2010-12-17	Novel antagonist antibodies and their fab fragments against gpvi and uses thereof

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG2012043956A SG181707A1 (en)	2009-12-18	2010-12-17	Novel antagonist antibodies and their fab fragments against gpvi and uses thereof

Country Status (29)

Country	Link
US (2)	US8852593B2 (es)
EP (2)	EP2933269A1 (es)
JP (1)	JP5843783B2 (es)
KR (1)	KR20120102125A (es)
CN (1)	CN102725309B (es)
AR (1)	AR079645A1 (es)
AU (1)	AU2010331807B2 (es)
BR (1)	BR112012014975A2 (es)
CA (1)	CA2784498A1 (es)
CL (1)	CL2012001650A1 (es)
CY (1)	CY1118389T1 (es)
DK (1)	DK2513147T3 (es)
EA (1)	EA201290525A1 (es)
ES (1)	ES2596254T3 (es)
HK (1)	HK1216537A1 (es)
HR (1)	HRP20161298T1 (es)
HU (1)	HUE029824T2 (es)
IL (1)	IL220447A0 (es)
LT (1)	LT2513147T (es)
MA (1)	MA33930B1 (es)
MX (2)	MX347613B (es)
PL (1)	PL2513147T3 (es)
PT (1)	PT2513147T (es)
SG (2)	SG10201405259PA (es)
SI (1)	SI2513147T1 (es)
TW (1)	TW201132759A (es)
UY (1)	UY33115A (es)
WO (1)	WO2011073954A2 (es)
ZA (1)	ZA201204421B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2691717T3 (es)	2009-10-30	2018-11-28	Novartis Ag	Bibliotecas universales del dominio de unión del lado inferior de tipo iii de la fibronectina de tipo III
KR20120102125A (ko) *	2009-12-18	2012-09-17	사노피	Ｇｐｖｉ에 대한 신규한 길항제 항체 및 그의 ｆａｂ 단편 및 그의 용도
EP2621953B1 (en)	2010-09-30	2017-04-05	Ablynx N.V.	Biological materials related to c-met
US11644471B2 (en)	2010-09-30	2023-05-09	Ablynx N.V.	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP3252076B1 (en)	2011-01-14	2019-09-04	The Regents Of The University Of California	Diagnostic use of antibodies against ror-1 protein
EP2723769B2 (en) *	2011-06-23	2022-06-15	Ablynx NV	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
EP2944653A1 (en) *	2011-06-23	2015-11-18	Ablynx N.V.	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
EP4350345A3 (en) *	2011-06-23	2024-07-24	Ablynx N.V.	Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains
EP2723771B1 (en)	2011-06-23	2019-09-11	Ablynx NV	Serum albumin binding proteins
EP2987806A3 (en) *	2011-08-17	2016-07-13	Glaxo Group Limited	Modified single variable domain antibodies with reduced binding to anti-drug-antibodies
US9346884B2 (en)	2011-09-30	2016-05-24	Ablynx N.V.	Biological materials related to c-Met
US9328174B2 (en)	2012-05-09	2016-05-03	Novartis Ag	Chemokine receptor binding polypeptides
JP2015531350A (ja) *	2012-09-13	2015-11-02	ノバルティスアーゲー	末端修飾を有する抗原結合分子
CN103396492A (zh) *	2013-08-06	2013-11-20	安徽新标志科技有限公司	抗人血小板胶原蛋白受体的人源性单克隆抗体片段及其应用
CN108289939B (zh) *	2015-08-05	2022-08-12	艾科迪科尔生物技术公司	抗人gpvi抗体及其用途
US11254734B2 (en)	2016-11-14	2022-02-22	Morphosys Ag	Fab molecules with a rodent hinge region and a non-rodent CH1 region
KR20240046168A (ko) *	2017-02-03	2024-04-08	액티코어 바이오테크	항-인간 gpvi 항체를 이용한 혈소판 응집의 억제
EP3793596A1 (en) *	2018-05-16	2021-03-24	MorphoSys AG	Antibodies targeting glycoprotein vi
GB202020602D0 (en) *	2020-12-24	2021-02-10	Univ Birmingham	Nanobody
WO2022257106A1 (zh) *	2021-06-11	2022-12-15	江苏丰华生物制药有限公司	一种人源化抗人GPVI单克隆抗体Fab片段及其应用
WO2023133470A2 (en) *	2022-01-07	2023-07-13	BioLegend, Inc.	Tmprss2 binding antibodies and antigen binding fragments thereof
EP4431526A1 (en)	2023-03-16	2024-09-18	Emfret Analytics GmbH & Co. KG	Anti-gpvi antibodies and functional fragments thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6451983B2 (en)	1989-08-07	2002-09-17	Peptech Limited	Tumor necrosis factor antibodies
US5919452A (en) *	1991-03-18	1999-07-06	New York University	Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
GB9109478D0 (en) *	1991-05-02	1991-06-26	Therapeutic Antibodies Inc	Antivenoms
US7062219B2 (en) *	1997-01-31	2006-06-13	Odyssey Thera Inc.	Protein fragment complementation assays for high-throughput and high-content screening
US7291714B1 (en) *	1999-06-30	2007-11-06	Millennium Pharmaceuticals, Inc.	Glycoprotein VI and uses thereof
US20040001826A1 (en)	1999-06-30	2004-01-01	Millennium Pharmaceuticals, Inc.	Glycoprotein VI and uses thereof
WO2001016321A1 (en) *	1999-09-01	2001-03-08	Otsuka Pharmaceutical Co., Ltd.	Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
WO2001032688A1 (en) *	1999-10-29	2001-05-10	Rutgers, The State University Of New Jersey	Renilla reniformis green fluorescent protein
US20030049701A1 (en) *	2000-09-29	2003-03-13	Muraca Patrick J.	Oncology tissue microarrays
EP1224942A1 (en) *	2001-01-23	2002-07-24	Bernhard Dr. Nieswandt	Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases
GB0130543D0 (en)	2001-12-20	2002-02-06	Univ Cambridge Tech	Human antibodies and their use
EP1538165A1 (en) *	2003-12-03	2005-06-08	Procorde GmbH	Inhibitors of glycoprotein VI based on monoclonal antibody hgp 5c4
GB0511590D0 (en)	2005-06-07	2005-07-13	Procorde Gmbh	Anti-thrombotic agents
EP1369128A1 (en) *	2002-06-07	2003-12-10	Procorde GmbH	Inhibitors of glycoprotein VI and their therapeutic use
US20070025992A1 (en) *	2003-07-18	2007-02-01	Mochida Pharmaceutical Co., Ltd	Monoclonal antibody against platelet membrane glycoprotein VI
US7598350B2 (en)	2004-03-19	2009-10-06	Imclone Llc	Human anti-epidermal growth factor receptor antibody
US7611707B2 (en) *	2004-04-29	2009-11-03	Otsuka Pharmaceutical Co., Ltd.	Glycoprotein VI antibodies and methods thereof
EP1824979A2 (en)	2004-12-10	2007-08-29	Trigen GmbH	Methods, products and uses involving platelets and/or the vasculature
GB0502358D0 (en) *	2005-02-04	2005-03-16	Novartis Ag	Organic compounds
WO2006117910A1 (ja) *	2005-04-28	2006-11-09	Mochida Pharmaceutical Co., Ltd.	抗血小板膜糖蛋白質ⅵモノクローナル抗体
JP5224707B2 (ja) *	2005-04-28	2013-07-03	持田製薬株式会社	抗血小板膜糖蛋白質ｖｉモノクローナル抗体
EP1876240B1 (en) *	2005-04-28	2012-08-22	Mochida Pharmaceutical Co., Ltd.	Anti-human platelet membrane glycoprotein vi monoclonal antibody
JPWO2007091719A1 (ja) *	2006-02-07	2009-07-02	持田製薬株式会社	抗ｇｐｖｉ抗体の併用療法及び新規医薬用途
JPWO2007116779A1 (ja)	2006-03-31	2009-08-20	持田製薬株式会社	新規血小板活性化マーカー及びその測定方法
EP1916259A1 (en) *	2006-10-26	2008-04-30	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Anti-glycoprotein VI SCFV fragment for treatment of thrombosis
SG10201407388XA (en)	2007-08-29	2015-01-29	Sanofi Aventis	Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
EP2212416A4 (en) *	2007-10-31	2013-01-09	Otsuka Pharma Co Ltd	USE OF A GLYCOPROTEIN VI (GPVI) INHIBITOR
MX2011004467A (es) *	2008-10-31	2011-07-28	Biogen Idec Inc	Moleculas de objetivo light y usos de las mismas.
KR20120102125A (ko) *	2009-12-18	2012-09-17	사노피	Ｇｐｖｉ에 대한 신규한 길항제 항체 및 그의 ｆａｂ 단편 및 그의 용도

2010
- 2010-12-17 KR KR1020127018655A patent/KR20120102125A/ko active IP Right Grant
- 2010-12-17 DK DK10813028.7T patent/DK2513147T3/en active
- 2010-12-17 AU AU2010331807A patent/AU2010331807B2/en not_active Ceased
- 2010-12-17 SG SG10201405259PA patent/SG10201405259PA/en unknown
- 2010-12-17 AR ARP100104712A patent/AR079645A1/es not_active Application Discontinuation
- 2010-12-17 PT PT108130287T patent/PT2513147T/pt unknown
- 2010-12-17 MA MA35073A patent/MA33930B1/fr unknown
- 2010-12-17 TW TW099144611A patent/TW201132759A/zh unknown
- 2010-12-17 WO PCT/IB2010/055917 patent/WO2011073954A2/en active Application Filing
- 2010-12-17 ES ES10813028.7T patent/ES2596254T3/es active Active
- 2010-12-17 UY UY33115A patent/UY33115A/es not_active Application Discontinuation
- 2010-12-17 HU HUE10813028A patent/HUE029824T2/en unknown
- 2010-12-17 LT LTEP10813028.7T patent/LT2513147T/lt unknown
- 2010-12-17 SI SI201031298A patent/SI2513147T1/sl unknown
- 2010-12-17 CN CN201080061679.5A patent/CN102725309B/zh not_active Expired - Fee Related
- 2010-12-17 CA CA2784498A patent/CA2784498A1/en not_active Abandoned
- 2010-12-17 EP EP15164863.1A patent/EP2933269A1/en not_active Withdrawn
- 2010-12-17 SG SG2012043956A patent/SG181707A1/en unknown
- 2010-12-17 JP JP2012543988A patent/JP5843783B2/ja not_active Expired - Fee Related
- 2010-12-17 MX MX2014005133A patent/MX347613B/es unknown
- 2010-12-17 BR BR112012014975A patent/BR112012014975A2/pt not_active IP Right Cessation
- 2010-12-17 MX MX2012007153A patent/MX2012007153A/es active IP Right Grant
- 2010-12-17 EP EP10813028.7A patent/EP2513147B1/en active Active
- 2010-12-17 EA EA201290525A patent/EA201290525A1/ru unknown
- 2010-12-17 PL PL10813028T patent/PL2513147T3/pl unknown
- 2010-12-17 US US13/515,650 patent/US8852593B2/en active Active
2012
- 2012-06-15 ZA ZA2012/04421A patent/ZA201204421B/en unknown
- 2012-06-17 IL IL220447A patent/IL220447A0/en unknown
- 2012-06-18 CL CL2012001650A patent/CL2012001650A1/es unknown
2014
- 2014-08-29 US US14/473,504 patent/US9441040B2/en active Active
2016
- 2016-04-19 HK HK16104453.4A patent/HK1216537A1/zh unknown
- 2016-10-07 HR HRP20161298TT patent/HRP20161298T1/hr unknown
- 2016-10-19 CY CY20161101056T patent/CY1118389T1/el unknown

Also Published As

Publication number	Publication date
HUE029824T2 (en)	2017-04-28
US9441040B2 (en)	2016-09-13
CL2012001650A1 (es)	2012-12-14
WO2011073954A3 (en)	2012-03-08
CY1118389T1 (el)	2017-06-28
MA33930B1 (fr)	2013-01-02
SI2513147T1 (sl)	2016-11-30
DK2513147T3 (en)	2016-10-24
EP2513147B1 (en)	2016-07-20
HRP20161298T1 (hr)	2016-11-18
PL2513147T3 (pl)	2017-08-31
AR079645A1 (es)	2012-02-08
KR20120102125A (ko)	2012-09-17
ES2596254T3 (es)	2017-01-05
ZA201204421B (en)	2013-09-25
US20150098939A1 (en)	2015-04-09
AU2010331807B2 (en)	2016-08-04
JP5843783B2 (ja)	2016-01-13
WO2011073954A2 (en)	2011-06-23
CN102725309B (zh)	2016-01-06
IL220447A0 (en)	2012-08-30
US8852593B2 (en)	2014-10-07
LT2513147T (lt)	2016-10-25
EP2933269A1 (en)	2015-10-21
MX2012007153A (es)	2012-07-03
SG181707A1 (en)	2012-07-30
CA2784498A1 (en)	2011-06-23
EA201290525A1 (ru)	2013-01-30
US20120244152A1 (en)	2012-09-27
JP2013514077A (ja)	2013-04-25
AU2010331807A1 (en)	2012-07-12
PT2513147T (pt)	2016-10-11
CN102725309A (zh)	2012-10-10
TW201132759A (en)	2011-10-01
HK1216537A1 (zh)	2016-11-18
BR112012014975A2 (pt)	2019-09-24
MX347613B (es)	2017-05-04
UY33115A (es)	2011-07-29
EP2513147A2 (en)	2012-10-24

Publication	Publication Date	Title
HK1216537A1 (zh)	2016-11-18	針對的新的拮抗劑抗體及其片段及其用途
GB0922434D0 (en)	2010-02-03	antibodies and fragments thereof
HK1216540A1 (zh)	2016-11-18	抗體及其用途
EP2494062A4 (en)	2013-05-29	ANTI-GLP-1R ANTIBODIES AND THEIR USES
HK1176940A1 (zh)	2013-08-09	單克隆抗體及其診斷用途
ZA201107486B (en)	2012-06-27	Anti-tnf-x antibodies and their uses
IL239604A0 (en)	2015-08-31	Antagonists against vegf and their uses
EP2525813A4 (en)	2013-07-10	ANTIBODIES TO ILT5 AND ILT5 BINDING ANTIBODY FRAGMENTS
PL2510011T3 (pl)	2015-02-27	Przeciwciała monoklonalne, które wiążą B7H6 i ich zastosowania
HK1167669A1 (en)	2012-12-07	Multispecific antibodies comprising full length antibodies and single chain fab fragments fab
ZA201108310B (en)	2013-04-24	Blocking anti-dkk-1 antibodies and their uses
IL215291A0 (en)	2011-12-29	NOVEL ANTI-a5BETA1 ANTIBODIES AND USES THEREOF
IL236237A (en)	2016-05-31	Tmem154 antibodies and their segments and uses
EP2593475A4 (en)	2014-03-05	ANTI-ADDL MONOCLONAL ANTIBODY AND USES THEREOF
IL220536A0 (en)	2012-08-30	Anti - bv8 antibodies and uses thereof
EP2399934A4 (en)	2013-03-20	NEW MONOCLONAL ANTIBODY AND USE THEREOF
GB0903151D0 (en)	2009-04-08	Antibody uses and methods
IL214527A0 (en)	2011-09-27	Anti-mst1r antibodies and uses thereof
IL208188A0 (en)	2010-12-30	Compositions comprising antibodies or antibody fragments
GB0906115D0 (en)	2009-05-20	Antibody and uses thereof